Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review

Rikisha Shah Gupta; Ardita Koteci; Ann Morgan; Peter M George; Jennifer K Quint

doi:10.1136/bmjresp-2022-001291

journal article Open Access Jun 01, 2023

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review

Rikisha Shah Gupta

Ardita Koteci Ann Morgan Peter M George Jennifer K Quint

BMJ Open Respiratory Research Vol. 10 No. 1 pp. e001291 · BMJ

View at Publisher Save 10.1136/bmjresp-2022-001291

Abstract

Interstitial lung disease (ILD) is a collective term representing a diverse group of pulmonary fibrotic and inflammatory conditions. Due to the diversity of ILD conditions, paucity of guidance and updates to diagnostic criteria over time, it has been challenging to precisely determine ILD incidence and prevalence. This systematic review provides a synthesis of published data at a global level and highlights gaps in the current knowledge base. Medline and Embase databases were searched systematically for studies reporting incidence and prevalence of various ILDs. Randomised controlled trials, case reports and conference abstracts were excluded. 80 studies were included, the most described subgroup was autoimmune-related ILD, and the most studied conditions were rheumatoid arthritis (RA)-associated ILD, systemic sclerosis associated (SSc) ILD and idiopathic pulmonary fibrosis (IPF). The prevalence of IPF was mostly established using healthcare datasets, whereas the prevalence of autoimmune ILD tended to be reported in smaller autoimmune cohorts. The prevalence of IPF ranged from 7 to 1650 per 100 000 persons. Prevalence of SSc ILD and RA ILD ranged from 26.1% to 88.1% and 0.6% to 63.7%, respectively. Significant heterogeneity was observed in the reported incidence of various ILD subtypes. This review demonstrates the challenges in establishing trends over time across regions and highlights a need to standardise ILD diagnostic criteria.PROSPERO registration number: CRD42020203035.

Topics

No keywords indexed for this article. Browse by subject →

References

108

[1]

10.1164/ajrccm.165.2.ats01

[2]

Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old

Ganesh Raghu, Shih-Yin Chen, Qiang Hou et al.

European Respiratory Journal 10.1183/13993003.01653-2015

[3]

Olson "Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis" Patient Relat Outcome Meas (2016)

[4]

Sun "Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020" Semin Arthritis Rheum (2021) 10.1016/j.semarthrit.2020.11.009

[5]

Sambataro "Patients with interstitial lung disease secondary to autoimmune diseases: how to recognize them?" Diagnostics (2020) 10.3390/diagnostics10040208

[6]

10.1016/j.semarthrit.2013.09.005

[7]

Deidda "Interstitial lung disease induced by fluoxetine: systematic review of literature and analysis of vigiaccess, eudravigilance and a national pharmacovigilance database" Pharmacol Res (2017) 10.1016/j.phrs.2017.04.010

[8]

10.1136/ard.2008.093690

[9]

Guo "The interstitial lung disease spectrum under a uniform diagnostic algorithm: a retrospective study of 1,945 individuals" J Thorac Dis (2020) 10.21037/jtd-19-4021

[10]

Global Burden of Disease Collaborative Network . Global burden of disease study 2019 (GBD 2019) reference life table. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME), 2021.

[11]

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J Page, Joanne E McKenzie, Patrick M Bossuyt et al.

BMJ 2021 10.1136/bmj.n71

[12]

Skeoch "Drug-induced interstitial lung disease: a systematic review" J Clin Med (2018) 10.3390/jcm7100356

[13]

Harari "Epidemiology of idiopathic pulmonary fibrosis in northern Italy" PLoS ONE (2016) 10.1371/journal.pone.0147072

[14]

Raimundo "Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study" BMC Pulm Med (2016) 10.1186/s12890-015-0165-1

[15]

Lee "Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea" Int J Tuberc Lung Dis (2016) 10.5588/ijtld.16.0003

[16]

Zhang N , Kaul B , Lee JS , et al . Epidemiology of idiopathic pulmonary fibrosis among U.S. veterans, 2010-2019. Ann Am Thorac Soc 2021.

[17]

10.1183/13993003.01504-2015

[18]

10.1007/s12325-018-0693-1

[19]

Kaunisto "Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis" BMC Pulm Med (2015) 10.1186/s12890-015-0074-3

[20]

10.3899/jrheum.201049

[21]

Li "Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study" Rheumatology (2021) 10.1093/rheumatology/keaa547

[22]

10.3899/jrheum.171315

[23]

10.1093/rheumatology/keaa836

[24]

Shin "Sex differences in clinical characteristics and their influence on clinical outcomes in an observational cohort of patients with rheumatoid arthritis" Jt Bone Spine (2021) 10.1016/j.jbspin.2020.105124

[25]

10.1007/s00296-017-3781-7

[26]

Kronzer "Respiratory diseases as risk factors for seropositive and seronegative rheumatoid arthritis and in relation to smoking" Arthritis Rheumatol (2021) 10.1002/art.41491

[27]

Kiely "Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERas and ERAN inception cohorts" BMJ Open (2019) 10.1136/bmjopen-2018-028466

[28]

Paulin "Lung involvement prevalence in patients with early rheumatoid arthritis without known pulmonary disease: a multicentric cross sectional study" Adv Rheumatol (2021) 10.1186/s42358-021-00209-0

[29]

10.1007/s10067-017-3561-5

[30]

10.1007/s40744-020-00267-8

[31]

Sakr "Rheumatoid arthritis: a single-center Egyptian experience" Immunol Invest (2018) 10.1080/08820139.2018.1425700

[32]

Samy "Rheumatoid arthritis patients with interstitial lung disease: clinical, radiological and laboratory characteristics" Egypt Rheumatol (2021) 10.1016/j.ejr.2020.08.004

[33]

Md Yusof "Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre" Rheumatology (2017) 10.1093/rheumatology/kex072

[34]

10.1093/rheumatology/kez177

[35]

McFarlane "Assessment of interstitial lung disease among black rheumatoid arthritis patients" Clin Rheumatol (2019) 10.1007/s10067-019-04760-6

[36]

Morrisroe "Incidence, risk factors, and outcomes of cancer in systemic sclerosis" Arthritis Care Res (Hoboken) (2020) 10.1002/acr.24076

[37]

Fairley "Clinical features of systemic sclerosis-mixed connective tissue disease and systemic sclerosis overlap syndromes" Arthritis Care Res (Hoboken) (2021) 10.1002/acr.24167

[38]

Noviani "Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort" Semin Arthritis Rheum (2020) 10.1016/j.semarthrit.2019.11.005

[39]

Vandecasteele "Incidence, prevalence and long-term progression of goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in Flanders: a retrospective cohort study" Semin Arthritis Rheum (2021) 10.1016/j.semarthrit.2021.07.018

[40]

Simeón-Aznar "Registry of the Spanish network for systemic sclerosis: survival, prognostic factors, and causes of death" Medicine (Baltimore) (2015) 10.1097/md.0000000000001728

[41]

Sánchez-Cano "Interstitial lung disease in systemic sclerosis: data from the Spanish scleroderma study group" Rheumatol Int (2018) 10.1007/s00296-017-3916-x

[42]

Jaafar S , Lescoat A , Huang S , et al . Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther 2021;23. doi:10.1186/s13075-021-02548-1 10.1186/s13075-021-02548-1

[43]

Bauer "Relationship between calcifications and structural lesions on hand radiography and axial calcifications on CT-scan: a retrospective study in systemic sclerosis" Medicine (Baltimore) (2020) 10.1097/md.0000000000022443

[44]

Janardana "Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma—do South Asians have a more aggressive disease?" Clin Rheumatol (2019) 10.1007/s10067-019-04659-2

[45]

Tomiyama "High prevalence of acute exacerbation of interstitial lung disease in Japanese patients with systemic sclerosis" Tohoku J Exp Med (2016) 10.1620/tjem.239.297

[46]

Wangkaew "Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study" Mod Rheumatol (2016) 10.3109/14397595.2015.1115455

[47]

Zhao "Primary Sjögren syndrome in Han Chinese: clinical and immunological characteristics of 483 patients" Medicine (Baltimore) (2015) 10.1097/md.0000000000000667

[48]

Roca "Interstitial lung disease in primary Sjögren’s syndrome" Autoimmun Rev (2017) 10.1016/j.autrev.2016.09.017

[49]

Kam "Clinical features and outcomes from the Singapore Sjögren’s syndrome study" Lupus (2021) 10.1177/0961203320976932

[50]

Gao "Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: a case-control study" Medicine (Baltimore) (2018) 10.1097/md.0000000000011003

Showing 50 of 108 references

Metrics

99

Citations

108

References

Details

Published: Jun 01, 2023
Vol/Issue: 10(1)
Pages: e001291
License: View

Authors

R

Rikisha Shah Gupta

National Heart and Lung Institute, Imperial College London, London, UK; Real-World Evidence, Gilead Sciences, Foster City, CA, USA

A

Ardita Koteci

Imperial College London, London, UK; NIHR Imperial Biomedical Research Centre, London, UK

A

Ann Morgan

Imperial College London, London, UK; NIHR Imperial Biomedical Research Centre, London, UK

P

Peter M George

Royal Brompton and Harefield NHS Foundation Trust, London, UK

J

Jennifer K Quint

National Heart and Lung Institute, Imperial College London, London, UK; Imperial College London, London, UK

Cite This Article

Rikisha Shah Gupta, Ardita Koteci, Ann Morgan, et al. (2023). Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review. BMJ Open Respiratory Research, 10(1), e001291. https://doi.org/10.1136/bmjresp-2022-001291

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review

You May Also Like